Disclaimer: The following content discusses our Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by our FDA-cleared RenovoCath. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoCath-enabled TAMP with gemcitabine for the treatment of locally advanced pancreatic cancer (LAPC) is being studied under an IND. This combination product candidate has not been approved by FDA for commercial use and its safety and effectiveness in treating LAPC has not been established. For RenovoCath’s Indications for Use and safety information, please visit IFU-10004-Rev.-G-Universal-IFU.pdf.
Released September 29, 2020
Last year, a 74-year old woman was diagnosed with inoperable pancreatic cancer. Her family turned to Miami Cancer Institute in their search for treatment options. Since her diagnosis, she became part of the TIGeR-PaC clinical trial, and is now in a maintenance phase and says her quality of life has improved.